Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Pulmonx Q2 2024 GAAP EPS $(0.39) Beats $(0.44) Estimate, Sales $20.783M Beat $20.134M Estimate

Author: Benzinga Newsdesk | July 31, 2024 04:36pm
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.44) by 11.36 percent. The company reported quarterly sales of $20.783 million which beat the analyst consensus estimate of $20.134 million by 3.23 percent. This is a 20.87 percent increase over sales of $17.194 million the same period last year.

Posted In: LUNG


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist